Delivering life changing gene therapies to their site of action

TargoPep works in collaboration with pharmaceutical R&D to design, research and refine targeted delivery solutions for gene therapy treatments.

TargoPep is a specialist in the delivery of oligotherapeutics

Our biological and chemical expertise, patented chemical solutions and innovative design principles enable our bespoke, peptide-based delivery systems to provide targeted drug delivery for your asset. Our technology overcomes barriers often associated with the clinical application of gene-based therapeutics.

Gene-based therapeutics, delivered safely and effectively to their site of action

Current solutions to the poor delivery of gene therapies rely on non-ideal and clinically limiting methods, which are expensive and time-consuming to adapt.

Our modular, dynamic and versatile approach enables TargoPep to address these delivery needs and expand the possibilities for, and potential of, gene therapies in the clinic. 

Gene-based therapeutics, delivered safely and effectively to their site of action

Current solutions to the poor delivery of gene therapies rely on non-ideal and clinically limiting methods, which are expensive and time-consuming to adapt.

Our modular, dynamic and versatile approach enables TargoPep to address these delivery needs and expand the possibilities for, and potential of, gene therapies in the clinic. 

Working seamlessly with your team, with your drug asset

TargoPep works in collaboration with your research team, to develop a bespoke solution that fully addresses your drug delivery needs. 

Providing delivery expertise, chemical solutions and assay development, the assets developed in collaboration with TargoPep maximise probability of success in the clinic.

Empower your R&D pipeline towards the clinic and life-changing applications

Augmenting your therapeutic pipeline with TargoPep’s unique delivery technologies accelerates those therapies towards the clinic and their markets.

TargoPep’s modularity and diversity of solutions provides for our clients, viable alternatives to other delivery options.

Latest news

We are thrilled to announce to our followers that TargoPep has been selected as finalist in the most recent Scottish Edge entrepreneurship competition.
Dr. Fergus McWhinnie, TargoPep’s CSO, looks at the story of oligotherapeutic approaches, the current success stories and the direction of research in the field that will provide future cures to today’s ‘uncurable’ diseases.
CEO Ken Fyvie explains the origins of TargoPep and how it will enable the effective delivery of transformative next-generation gene therapies.

Team TargoPep